GW583340 dihydrochloride

Cat. No.: HY-103439 CAS No.: 1173023-85-2 Molecular Formula: $C_{28}H_{27}CI_{3}FN_{5}O_{3}S_{2}$

Molecular Weight: 671.03 Target: **EGFR**

Pathway: JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

HCI HCI

Product Data Sheet

BIOLOGICAL ACTIVITY

Description	GW 583340 dihydrochloride is a potent dual EGFR/ErbB2 tyrosine kinase inhibitor (IC $_{50}$: 0.01 and 0.014 μ M respectively). GW 583340 dihydrochloride reverses ABCG2- and ABCB1-mediated drug resistance. GW 583340 dihydrochloride has anti-cancer activity [1][2][3].
In Vitro	GW 583340 dihydrochloride (5 μ M) decreases the IC ₅₀ values of Mitoxantrone in inhibition of ABCG2-482-R2 and ABCG2-482-T7 cell lines ^[1] . GW 583340 dihydrochloride (2.5 and 7.5 μ M, 24 h) increases in ROS accumulation in both SUM149 and SUM190 cells, and induces cell apoptosis ^[2] . GW 583340 dihydrochloride (0-10 μ M) reduces the colony formation in SCCF1 cells and CatMC cells ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Sodani K, et al. GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. Biochem Pharmacol. 2012 Jun 15;83(12):1613-22.

[2]. Aird KM, et al. ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res Treat. 2012 Feb;132(1):109-19.

[3]. Gray ME,et al. Dual targeting of EGFR and ERBB2 pathways produces a synergistic effect on cancer cell proliferation and migration in vitro. Vet Comp Oncol. 2017 Sep;15(3):890-909.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA